Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Preeclampsia is a pregnancy-specific syndrome that affects 3 - 5% of pregnancies. It is one
of the main causes of maternal, fetal and neonatal morbidity and mortality, resulting in
approximately 40,000 maternal deaths worldwide each year. Fortunately, preeclampsia-related
deaths have been reduced remarkably in recent decades thanks to improvements in antenatal
care and therapeutic interventions, and prophylactic use of low-dose aspirin in women who are
at a higher risk of developing preeclampsia.
Effective prevention is rarely available for obstetric complications. Aspirin is one of them.
Several meta-analyses456 suggested that aspirin prescription reduced the risk of preeclampsia
and fetal growth restriction by 40-50% in an aspirin-dose-response pattern.